Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Clinical trial NCT02116660 · TERMINATED
Trial details
- NCT number
- NCT02116660
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-03
- Primary completion
- 2017-07-10
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.